Literature DB >> 27523972

Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.

Adrián Mariño-Enríquez1, Judith V M G Bovée2.   

Abstract

Sarcomas are infrequent mesenchymal neoplasms characterized by notable morphological and molecular heterogeneity. Molecular studies in sarcoma provide refinements to morphologic classification, and contribute diagnostic information (frequently), prognostic stratification (rarely) and predict therapeutic response (occasionally). Herein, we summarize the major molecular mechanisms underlying sarcoma pathogenesis and present clinically useful diagnostic, prognostic and predictive molecular markers for sarcoma. Five major molecular alterations are discussed, illustrated with representative sarcoma types, including 1. the presence of chimeric transcription factors, in vascular tumors; 2. abnormal kinase signaling, in gastrointestinal stromal tumor; 3. epigenetic deregulation, in chondrosarcoma, chondroblastoma, and other tumors; 4. deregulated cell survival and proliferation, due to focal copy number alterations, in dedifferentiated liposarcoma; 5. extreme genomic instability, in conventional osteosarcoma as a representative example of sarcomas with highly complex karyotype.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone; GIST; Molecular diagnostics; Molecular markers; Sarcoma; Soft tissue tumor

Mesh:

Substances:

Year:  2016        PMID: 27523972      PMCID: PMC4988391          DOI: 10.1016/j.path.2016.04.009

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  115 in total

1.  Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

Authors:  R P DeMatteo; J J Lewis; D Leung; S S Mudan; J M Woodruff; M F Brennan
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.

Authors:  Giuseppe Floris; Agnieszka Wozniak; Raf Sciot; Haifu Li; Lori Friedman; Thomas Van Looy; Jasmien Wellens; Peter Vermaelen; Christophe M Deroose; Jonathan A Fletcher; Maria Debiec-Rychter; Patrick Schöffski
Journal:  Clin Cancer Res       Date:  2012-12-11       Impact factor: 12.531

3.  Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations.

Authors:  Katherine A Janeway; Su Young Kim; Maya Lodish; Vânia Nosé; Pierre Rustin; José Gaal; Patricia L M Dahia; Bernadette Liegl; Evan R Ball; Margarita Raygada; Angela H Lai; Lorna Kelly; Jason L Hornick; Maureen O'Sullivan; Ronald R de Krijger; Winand N M Dinjens; George D Demetri; Cristina R Antonescu; Jonathan A Fletcher; Lee Helman; Constantine A Stratakis
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

4.  Frequent FOS Gene Rearrangements in Epithelioid Hemangioma: A Molecular Study of 58 Cases With Morphologic Reappraisal.

Authors:  Shih-Chiang Huang; Lei Zhang; Yun-Shao Sung; Chun-Liang Chen; Thomas Krausz; Brendan C Dickson; Yu-Chien Kao; Narasimhan P Agaram; Christopher D M Fletcher; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2015-10       Impact factor: 6.394

5.  Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

Authors:  Michael C Heinrich; Christopher L Corless; Charles D Blanke; George D Demetri; Heikki Joensuu; Peter J Roberts; Burton L Eisenberg; Margaret von Mehren; Christopher D M Fletcher; Katrin Sandau; Karen McDougall; Wen-bin Ou; Chang-Jie Chen; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2006-09-05       Impact factor: 44.544

6.  Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs).

Authors:  Anette Duensing; Fabiola Medeiros; Bryna McConarty; Nora E Joseph; Dipak Panigrahy; Samuel Singer; Christopher D M Fletcher; George D Demetri; Jonathan A Fletcher
Journal:  Oncogene       Date:  2004-05-13       Impact factor: 9.867

7.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST.

Authors:  B Liegl; I Kepten; C Le; M Zhu; G D Demetri; M C Heinrich; C D M Fletcher; C L Corless; J A Fletcher
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

Review 8.  New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype.

Authors:  Jamie Lim; Neal M Poulin; Torsten O Nielsen
Journal:  Clin Cancer Res       Date:  2015-09-01       Impact factor: 12.531

9.  Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy.

Authors:  Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree
Journal:  Nat Genet       Date:  2013-05-05       Impact factor: 38.330

10.  Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

Authors:  Wei Xu; Hui Yang; Ying Liu; Ying Yang; Ping Wang; Se-Hee Kim; Shinsuke Ito; Chen Yang; Pu Wang; Meng-Tao Xiao; Li-xia Liu; Wen-qing Jiang; Jing Liu; Jin-ye Zhang; Bin Wang; Stephen Frye; Yi Zhang; Yan-hui Xu; Qun-ying Lei; Kun-Liang Guan; Shi-min Zhao; Yue Xiong
Journal:  Cancer Cell       Date:  2011-01-18       Impact factor: 38.585

View more
  9 in total

1.  Elevated circulating macrophage inhibitory cytokine 1 is a biological marker for the diagnosis and prognosis of osteosarcoma.

Authors:  Xianxiang Song; Lijun Tian; Yanqiu Quan; Dan Sun; Linmei Zhang
Journal:  Exp Ther Med       Date:  2018-09-21       Impact factor: 2.447

2.  Over-methylation of Histone H3 Lysines Is a Common Molecular Change Among the Three Major Types of Soft-tissue Sarcoma in Patient-derived Xenograft (PDX) Mouse Models.

Authors:  Yusuke Aoki; Jun Yamamoto; Yasunori Tome; Kazuyuki Hamada; Noriyuki Masaki; Sachiko Inubushi; Yoshihiko Tashiro; Michael Bouvet; Itaru Endo; Kotaro Nishida; Robert M Hoffman
Journal:  Cancer Genomics Proteomics       Date:  2021 Nov-Dec       Impact factor: 4.069

3.  Involvement of c-Fos in cell proliferation, migration, and invasion in osteosarcoma cells accompanied by altered expression of Wnt2 and Fzd9.

Authors:  Qiaozhen Wang; Huancai Liu; Qing Wang; Fenghua Zhou; Yongxin Liu; Yawen Zhang; Haoyu Ding; Meng Yuan; Fengjie Li; Yanchun Chen
Journal:  PLoS One       Date:  2017-06-30       Impact factor: 3.240

Review 4.  Potentials of Long Noncoding RNAs (LncRNAs) in Sarcoma: From Biomarkers to Therapeutic Targets.

Authors:  Li Min; Cassandra Garbutt; Chongqi Tu; Francis Hornicek; Zhenfeng Duan
Journal:  Int J Mol Sci       Date:  2017-03-29       Impact factor: 5.923

5.  SP1-Induced Upregulation of lncRNA LINC00514 Promotes Tumor Proliferation and Metastasis in Osteosarcoma by Regulating miR-708.

Authors:  Li-Dong Mi; Chuan-Xiu Sun; Sheng-Wei He; Guang-Yu Du
Journal:  Cancer Manag Res       Date:  2020-05-11       Impact factor: 3.989

Review 6.  Non-gastrointestinal stromal tumours soft tissue sarcomas: an update.

Authors:  Gustavo Duarte Ramos Matos; Veridiana Pires de Camargo; Rodrigo Ramella Munhoz; Gilberto de Castro
Journal:  Ecancermedicalscience       Date:  2019-08-13

Review 7.  The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.

Authors:  Sioletic Stefano; Scambia Giovanni
Journal:  Cancers (Basel)       Date:  2019-08-14       Impact factor: 6.639

8.  Pyroptosis-Related Gene Signature Is a Novel Prognostic Biomarker for Sarcoma Patients.

Authors:  Dalong Wei; Xiaoling Lan; Zhiqun Huang; Qiang Tang; Zechen Wang; Yanfei Ma; Liuzhi Wei; Qiuju Wei; Jingjie Zhao; Jiajia Shen; Siyuan He; Jian Song; Lingzhang Meng; Qianli Tang
Journal:  Dis Markers       Date:  2021-12-03       Impact factor: 3.434

9.  Accuracy of core needle biopsy for histologic diagnosis of soft tissue sarcoma.

Authors:  J Kiefer; M Mutschler; Ph Kurz; G B Stark; H Bannasch; F Simunovic
Journal:  Sci Rep       Date:  2022-02-03       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.